# Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO

> **Open Intelligence Dossier** · First detected: 2026-10-27 06:00 UTC · Category: Business

## Executive Summary
Incyte presents new early clinical data at ESMO for its KRAS G12D-targeted pancreatic and colorectal cancer medicine.

## Intelligence Brief
Recent coverage across multiple specialized publications tracks developments from Incyte regarding its gastrointestinal cancer portfolio at the ESMO 2026 meeting. According to reporting from outlets including STAT, Fierce Biotech, TradingView, OncLive, Press Release Hub, GuruFocus, and FirstWord Pharma, the company highlighted early results for a KRAS drug targeting pancreatic and colorectal cancers. Specifically, OncLive and STAT detailed findings on INCB161734 administered in combination with chemotherapy, noting that the regimen continues to elicit responses in patients with KRAS G12D-mutated pancreatic ductal adenocarcinoma, referred to as PDAC. Coverage heavily emphasizes the competitive landscape surrounding these targeted therapies, with Fierce Biotech reporting that Incyte views its pipeline as neck and neck with RevMed in the ongoing KRAS G12D pancreatic cancer race.


TradingView and Press Release Hub added that these promising data concerning KRAS G12D and bispecific compounds serve to strengthen the company&amp;#039;s broader late-stage gastrointestinal cancer programs. Corporate transcripts published via GuruFocus and press releases distributed through Press Release Hub provided additional context on the company&amp;#039;s presentation of these gastrointestinal assets to investors and industry observers during the medical meeting. The context provided by the reporting situates these disclosures within ongoing oncology research efforts targeting specific genetic mutations in difficult-to-treat gastrointestinal malignancies. KRAS G12D mutations are a known focus for drug developers addressing pancreatic and colorectal cancers, and scientific updates at major congresses such as ESMO are standard venues for presenting early-phase clinical data.


Coverage does not yet specify full trial completion dates or regulatory submission timelines, noting instead that the current focus remains on early results and portfolio advancement. Observers tracking these trends will look to future medical congresses and corporate communications for subsequent data updates on the INCB161734 regimen and the wider gastrointestinal portfolio. As reporting from FirstWord Pharma and STAT indicates, further evaluation of durability and combination strategies will dictate how the candidate progresses through clinical evaluation. Coverage does not currently detail the exact next milestones or when extended trial cohorts will report findings, leaving stakeholders to monitor upcoming company updates.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| FirstWord Pharma | ESMO26: Incyte touts early results for KRAS drug in pancreatic, colorectal cancers | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTFBON3BzN21Oc3ZLakdJMnlIbGVEc0VwTktidEtjdnJXOWl6VGxtR1FnQjJOYjFfVUtCaGlPM1g4SklWckJ5UHJsWHNUcnhHa2JxMjRR?oc=5) |
| GuruFocus | Incyte Corp at ESMO Transcript | [Source Link](https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5aWFdiS0lfbnJYYU1oRG5HZXFlRkRITXQzdTBjTHFNSl9ucVRaVWZtT3lJQ1lYSzlWVkI5aVdwNnpadnBvakZ6ZkM3Qm5JWjVhLUFJV09IM3FnQmRuR2pvTjczV0tlYXM?oc=5) |
| Press Release Hub | Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026 | [Source Link](https://news.google.com/rss/articles/CBMi1gFBVV95cUxOVGVsSkZPYVNWN2lZRWQxVGNBT01UVldGcDMwbGFobENBVElQV25WaF9GUlpmTlJ3ejRLdTljaHdlb1JsMThQaVdTbTJiaGxmdzFFOTJBLTAtNll2TG02cTlDa1BnNm4wZVI4MkhiUTh5cjIzQmc4SWN5UG9CM2RSMFZVLU1BOUVUQWp0Y25zQzRDVnNjcDQzWU12aDFhNWw5UXQzRi1lempmcE1ORzdWV2liRVFTWUNlZjFmemFSdVQ4X3NpbWRnNGxPX2JnM1ZJSUNBRjN3?oc=5) |
| OncLive | INCB161734 Plus Chemotherapy Continues to Elicit Responses in KRAS G12D–Mutated PDAC | [Source Link](https://news.google.com/rss/articles/CBMiswFBVV95cUxNN3JUSXFSc3hjc0ZRWjBZTDktZUNIYVVWbWRjUXNsUDd2WU9RaExOR3BKMlAtOEFROXBhcF9vOWRvMUY2eUEtaHhBWHlFYlp2LXFVTHo2S0tCZmxNaGpmdEtoQ2VlNDI5TTRlbVVUT01xVU1nM2h2WlV6Yk5Ic1RmNTd3U1c4R1M3aGxJei1QWVJwSUxhUWJ2eUVBamhPc3NSa3JQakxkdUp6eHFRSjZ5YUhQZw?oc=5) |
| TradingView | INCY: Promising KRAS G12D and bispecific data strengthen late-stage GI cancer programs | [Source Link](https://news.google.com/rss/articles/CBMi_AFBVV95cUxOZWVidE9Pa1RKeE1udlZ6NW9zdVBxN0N0MTVaenZhMjJIMGhMQTNqMHVVNFBRUW1xYXl0aWpFTDAzZXBYQnhPOFZJLVRFUW9Nd2RHOU5JaDh1bmdVMXN6Y2NMY1NNT2FOaldjU28xdGZLVWZ2VVptN0xPaldXZWFEZE00RXpfeHp4ajNmQUYzLU02SHFzclVfWjVwSGdfREVIeU54Ykh5WXFpR3RWY01iR0tadFNZNEswSl9icm5pVzVPQTg0cHZZQWt0Rm00QWttVnlvMy02bG0tS2V6blZwbnlCdVczSFY5MHNFOVdvbmRienV4TlBWTmFWWmM?oc=5) |
| Fierce Biotech | ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxOeWpya29fU2s3MVFCdGNMRG9oUkwxd0l4Z3BEbi1xNG14UzQwT3o0YVpubl9KSjNUZXlwd21RemRQalg3ZkxpRklHZ2l4V3dlcG5ZVThzRXJLTVJxLTJ5dHljTjJIOUhHakx2S2lKeHJhU0dJWjk4MHRnRzVvLTBrS3NyZVFUZUxQRjZCMWdxNEdTV0ljdkZ2YUVBb0d0WEFjS1pn?oc=5) |
| STAT | Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO | [Source Link](https://news.google.com/rss/articles/CBMijgFBVV95cUxONnY1aHA0UER3TlpIMkVTQnpLVHV1R2o5R3JVeUpHNDd6NEQ1WllaRV9pRXg4S2lpTlptaDhnZTJlNV9ST2lhZXI4cG44LTBjM3VSVUxoelVTUWxBUkUtNXBXY3pnZ3RwOERTVjhHbGo1bHBvcER0NC1ERzdpWnhialhpVGxITEVZa1VTM3ZR?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-10-27/incyte-pancreatic-cancer-medicine-induces-lasting-tumor-responses-company-says*
